Sie sind auf Seite 1von 3

FOR IMMEDIATE RELEASE:

Eularis Analyzes Most Effective Generics Defense Strategies with New


Pharmaceutical Industry Report
Branded Pharmaceutical companies can expect to see sales drops of up to 70
percent after patent expiration from Generic competition
NEW YORK, N.Y. and TOKYO, JAPAN, July 13, 2008 (SEND2PRESS NEWSWIRE) --
Branded Pharmaceutical companies are painfully aware of the astronomical
growth of Generics competition. By the end of this year, Branded drug patents
accounting for sales of more than $80 Billion will expire, resulting in major
losses in company profits. In the United States, the Generics Industry claims
more than 50 percent of all prescriptions filled. Even in Japan, where
Generics penetration is notoriously low, changes are afoot. The government has
taken note from countries like the U.S. and instructed all national hospitals
to actively use Generics. Now, in Japan, doctors and pharmacists can collect
additional fees for prescribing and dispensing Generics. Combine these trends
with a growing number of Japanese blockbuster drugs facing patent expiration
and the Generics penetration rate is poised to expand in coming years, even in
the 'Generics-proof' Japanese market. To address this globally alarming issue,
Eularis announces today the availability of their new report, "How to Plan an
Effective Generics Defense Strategy: Planning, Tactics and Implementation."
*(PHOTO Link 72dpi: Send2Press.com/mediaboom/08-0714-AnBates_72dpi.jpg)
*(Photo Caption: Dr. Andree K. Bates, President of Eularis.)
Written for CEO's, Marketing Executives and Sales Executives, this report
uncovers the factors working for Generics growth and the barriers against it,
offering secrets the Generics Industry doesn't want you to know. The report
includes case studies of how to analyze where weaknesses exist within your
Generics competitors and what to do about it. The report discusses appropriate
tactics to improve competitiveness with Generics and demonstrates
implementation methods and issues. The report delves into specific marketing
situations - such as USA, Europe and Japan - and identifies issues relevant to
each market.
"Pharmaceutical companies need to seriously reconsider their approach to
solving the Generics problem," commented Dr. Andree K. Bates, author of the
report and President of Eularis. "The Generics threat is very real, and
growing. However, Generics are not all-powerful, invulnerable competitors. To
truly mount an effective defense against Generics, companies must realize
what's hurting Generic growth and use these issues to develop a path that
works to help Branded Pharma."

Effective defense strategies exist that employ a variety of reactive and


proactive measures. More importantly, the report shows that the Generics
Industry is facing some powerful challenges and damaging growing pains in its
path towards dominance. To truly understand the Pharma Industry's ability to
deflect the Generics threat, companies must know the best defense strategies.
However, they also must know the reality of what's happening in the Generics
realm.
Bates has gained wide recognition within the international Pharmaceutical
Industry for her expertise in Pharmaceutical Marketing Analysis. In addition
to this and other must-have reports for Pharmaceutical Industry marketers, she
has authored many articles in peer-reviewed journals and several chapters in
books on Pharmaceutical Analytics.

To purchase the Eularis report, "How to Plan an Effective Generics Defense


Strategy: Planning, Tactics and Implementation," visit:
http://www.genericsdefensestrategies.com/ or, for more information about
Eularis, visit www.eularis.com
ABOUT EULARIS
Eularis provides sophisticated Pharmaceutical analytics that provide data-
driven insight into the financial impact of corporate and marketing decisions.
Unlike traditional analytics approaches, which are lengthy and whose reliance
on historical or analogue data reduces their accuracy, Eularis' proprietary
94.8 Analytics Process is based on the current market situation. This proven
approach helps Pharmaceutical marketing teams to quickly plan, measure,
validate and optimize their sales and marketing performance.
Eularis offers pre-launch analytics, marketing mix modeling (both professional
and consumer), portfolio optimization, sales force effectiveness, Managed Care
analytics, patient compliance solutions and Generics defense analysis
strategies. With offices in London, New York and Tokyo, the company has
developed significant experience in the global Pharmaceutical market through
client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many
others.

For more information about Eularis, visit http://www.eularis.com.


All trademarks acknowledged.

Send2Press(R) is the originating wire service for this story.

NEWS SOURCE: Eularis

# # #
//RELEASE END//

MEDIA ONLY CONTACT(S):

[ contact info not for publication online or in print ]

Yuko Muta
Eularis
+44 20 7403 5378
YMuta @ Eularis.com

/Note to editors:
Additional Eularis news and RSS feed (English):
http://www.send2press.com/newswire/Eularis.shtml

.........
Plain Text Copy, and Story Permalink:
http://www.Send2Press.com/mediadrome/2008-07-0713-001.txt
Release PDF:
http://www.Send2Press.com/mediadrome/news_2008-07-0713-001.pdf

Get our full-text news via RSS:


http://www.Send2Press.com/RSS2/rss.xml

.........
Text provided by news source (and/or the source's authorized agency), who is
solely responsible for accuracy and legality of content transmitted.
.........

This news story from Send2Press Newswire may be redistributed and re-posted in
part or in whole by members of the media. Copr. (c) Send2Press, a unit of
Neotrope(R). For news aggregation sites, blogs, and bureaus, you must retain
Send2Press as the original wire service source. You may capture and self-host
images linked to in above release, but do NOT stream from our server.

.........
The original version of this release was issued on behalf of the above
organization (the "news source"), by Send2Press(R) Newswire, a unit of
Neotrope(R). http://www.Send2Press.com.
.........
July 2008 Press Release
/ B-IND JPN / IND: MED PHARM RES ADV
/ REF: Advertising Industry Newswire(TM)
/

Das könnte Ihnen auch gefallen